A major expert commission finds thousands of avoidable deaths from liver disease across Europe and urges stronger policies to curb alcohol, obesity, and viral risks
The health landscape in Europe has a growing, often unnoticed problem: rising mortality from liver disease. A cross-disciplinary panel of clinicians, economists and public health experts convened by the EASL–Lancet Commission has assessed this burden and concluded that many fatalities could be prevented through smarter policy and better clinical strategies.
The report highlights a combination of lifestyle, commercial and clinical drivers that together explain why deaths from cirrhosis and liver cancer continue to climb even as many other major non-communicable diseases stabilise.
Below we unpack the scale of the problem, the shifting causes behind it, and the interventions experts say would deliver the most impact.
Throughout this article, key terms such as MASLD and cirrhosis are emphasised to draw attention to the technical concepts policymakers and clinicians must confront.
Scale and economic impact of the epidemic
The commission estimates that around 284,000 deaths in Europe each year are attributable to advanced liver conditions, which equates to nearly 780 deaths per day.
Within that total, deaths from liver cancer have climbed by more than 50% since 2000, reaching roughly 69,000 in 2026. Beyond lives lost, the financial toll is substantial: liver disease reduces regional economic output by about €55 billion annually, roughly 0.3% of GDP when lost productivity, premature mortality and workforce absence are combined. These figures underline that liver health is both a humanitarian and an economic priority.
Changing causes: from alcohol to metabolic illness
Where liver damage was once mostly associated with long-term heavy drinking, the pattern has shifted. Alcohol remains a major contributor, but rising levels of obesity, unhealthy diets and metabolic disorders now drive a large and growing share of cases. The report stresses the importance of metabolic dysfunction-associated steatotic liver disease — labelled MASLD — as a principal cause. MASLD arises in the context of excess weight, insulin resistance and other features of metabolic syndrome, and it increasingly explains liver disease in people who drink little or no alcohol.
MASLD progression and clinical challenges
MASLD typically develops silently over years: fat accumulation precedes inflammation and scarring, and eventually some patients progress to cirrhosis, liver failure, or liver cancer. Because early stages are often asymptomatic, many people are diagnosed only after substantial damage has occurred. The report therefore recommends expanding screening and improving pathways for early detection, so that interventions can halt or reverse disease trajectories before advanced complications emerge.
Commercial determinants and young people
The commission places significant emphasis on how industry practices shape risk. Cheap pricing, widespread promotion and the omnipresence of marketing for alcohol and ultra-processed foods help normalise harmful patterns. Digital platforms and social media algorithms in particular are cited for increasing young people’s exposure to content that promotes alcohol use and unhealthy diets. Addressing these commercial determinants of health is seen as crucial if policy aims to reduce population-level risk rather than rely solely on individual behaviour change.
Policy options with strong evidence
Experts recommend a set of interventions that span regulation, health services and prevention. High-priority measures include: imposing effective alcohol pricing and taxation, introducing health warning labels on alcohol, restricting digital marketing targeted at adolescents, expanding viral hepatitis testing and treatment for underserved groups, and integrating liver care within broader non-communicable disease frameworks. The commission also urges coordinated procurement strategies to improve access to affordable medicines and the inclusion of liver health metrics in monitoring systems to ensure accountability.
Voices from patient groups and academics underscore the urgency. Campaigners argue that making harmful products less cheap and less aggressively promoted is a matter of fairness, not paternalism. Public health academics stress that Europe already has the tools to reverse these trends if political will is marshalled: prevention, earlier diagnosis and integrated care would substantially reduce deaths and economic losses. In short, the report frames liver disease as a preventable crisis that requires both clinical action and structural policy reform to protect current and future generations.
